| Name | Title | Contact Details |
|---|
Medi-EMR is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Black & Black Surgical is a Tucker, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The all-in-one digital solution for gut health and disease. We`re helping people feel better, while lowering their cost of care. At Vivante, we`re taking on digestive disease because an astonishing 70 million people in the US are affected—that`s twice the number with diabetes and more than many other chronic conditions combined. Unlike other chronic conditions, though, digestive diseases are often untreated or misdiagnosed...because of stigma. Over half of adults with digestive trouble admit they haven`t even consulted a provider about their symptoms. This is unfortunate because chronic digestive symptoms take a toll on home life, work performance, romance, and even simple social events. And digestive disease is expensive! For most companies, GI claims are the #2 healthcare expense, second only to cancer. Specialty drugs for inflammatory bowel disease can run $70k per year for just ONE employee. Now is the time for employers and health plans to address digestive health, while at the same time providing REAL help to the millions who are struggling and don`t know where to turn. Our all-in-one digital program, GIThrive®, empowers people—through brilliant technology and advanced science—to spend less time worrying about their digestive symptoms and more time living life. A wonderful byproduct of the GIThrive success is reduced medical and Rx drug spending for employers, health plans and individuals.
Boston Brace International is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Boston Brace International is based in Avon, MA. You can find more information on Boston Brace International at www.bostonbrace.com
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.